KeyBanc on Lifecore Biomedical (LFCR): 'Recent Announcements Indicate Momentum & Strategic Value Is Building'

KeyBanc analyst Paul Knight reiterated a Sector Weight rating on Lifecore Biomedical (NASDAQ: LFCR).

The analyst commented: "Recent Announcements Indicate Momentum & Strategic Value Is Building at LFCR; In our view, recent announcements suggest momentum is building at LFCR and, with over $370B in onshoring planned (Source: Contract Pharma), more deals are likely. We highlight that the recent tech. transfer win, following another large win announced with earnings, has top 5 commercial customer potential. Also, LFCR was added to the Nasdaq Biotech Index on Dec. 22nd, which may increase investor awareness. While revenue is not expected to step higher until CY27, we believe visibility on the outer years is improving and that LFCR's focus on fill/finish continues to have potential strategic value."

For an analyst ratings summary and ratings history on Lifecore Biomedical click here. For more ratings news on Lifecore Biomedical click here.

Shares of Lifecore Biomedical closed at $8.30 yesterday.

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
• Stripe, Advent In Talks To Buy Paypal - WSJ